Documentation of published clinical trials and ... - Institut Hiscia
Documentation of published clinical trials and ... - Institut Hiscia
Documentation of published clinical trials and ... - Institut Hiscia
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Survival Urogenital Cancer Bladder 5.1.1.2<br />
H<strong>of</strong>fmann J. (1978) Beh<strong>and</strong>lungsergebnisse bei den Blasenkarzinomen der Lukas Klinik. [Results<br />
<strong>of</strong> treatment <strong>of</strong> cancer <strong>of</strong> the bladder in the Lukas Clinic.] Mitteilungen aus der Beh<strong>and</strong>lung<br />
maligner Tumoren mit Viscum album 10 (2), 6–11.<br />
Study design<br />
Design Retrospective study with 2 groups.<br />
Patients 103 patients with cancer <strong>of</strong> the bladder, who were being treated on the<br />
reference date: 30.9.1977. Their initial diagnosis was at least 5 years<br />
previous <strong>and</strong> histologically secured.<br />
Treatment Iscador s.c. in different doses. One group <strong>of</strong> 17 patients received<br />
inadequate doses <strong>of</strong> Iscador, for various reasons.<br />
Length <strong>of</strong> study 1963–1977.<br />
Measurement Survival.<br />
Most important results<br />
The 5- <strong>and</strong> 10-year rates <strong>of</strong> survival were 35% <strong>and</strong> 30% respectively. The mean survival <strong>of</strong> the<br />
patients who died during the treatment, whose disease had been diagnosed as stage IV, was<br />
better under Iscador therapy. These patients survived 23.6 months in comparison to 9.2 months<br />
in the group <strong>of</strong> the 17 patients, with stage II-IV, who received inadequate Iscador doses. The<br />
differences are not statistically significant.<br />
© Verein für Krebsforschung, CH-4144 Arlesheim
Change language